JAK2 and breast cancer: Withaferin A activity has been found to modulate the JAK/STAT pathway in human breast cancer cells by decreasing phosphorylation of STAT3 and JAK2 in MDA-MB-231 breast cancer cell line (Lee et al., 2010).